Home / Resource Library / Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

Cost-effectiveness of polatuzumab vedotin plus chemoimmunotherapy for untreated diffuse large B-cell lymphoma in China

Study examined cost-effectiveness of polatuzumab vedotin for treatment of DLBCL in China.